Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01421524 · ClinicalTrials.gov registry record · Phase 1
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Lymphoma, sponsored by Celgene.
- Completed
- Registry status
- Phase 1
- Development phase
- 271
- Enrollment target
- 20
- Study locations
NCT01421524 is a Phase 1 study of Multiple Myeloma and Lymphoma that has completed, run by Celgene. The registered enrollment target is 271 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01421524, a Phase 1 study of Multiple Myeloma and Lymphoma, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 271 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials.
Conditions Studied
Interventions
- DRUG CC-122
Study Locations (20)
California
- City of Hope Cancer Center - Duarte
- UCLA Neuro-Oncology Program - Los Angeles
- UCSF Helen Diller Medical Center at Parnassus Heights - San Francisco
Other
- Local Institution - 401 - Brussels
- Local Institution - 400 - Leuven
- Local Institution - 202 - Caen
Michigan
- University Of Michigan Comprehensive Cancer Center - Ann Arbor
- Henry Ford Medical Center - New Center One - Detroit
New York
- Mount Sinai Hospital - New York
- Local Institution - 020 - New York
South Carolina
- MUSC Rheumatology and Immunology Dept. - Charleston
- Greenville Hospital System - Greenville
Texas
- Texas Oncology, PA - Dallas 75246 - Dallas
- South Texas Accelerated Research Therapeutics (START) - San Antonio
Washington
- Swedish Medical Center Cancer Institute Research - Seattle
- Yakima Valley Memorial Hospital/ North Star Lodge - Yakima
Nevada
- Comprehensive Cancer Centers Of Nevada - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 271 participants |
| Start Date | 2011-09-12 |
| Est. Completion | 2023-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01421524
The ClinicalTrials.gov registry entry for NCT01421524 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (50% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention - of which CC-122 is the first listed.
NCT01421524 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Other, Michigan.
Frequently Asked Questions
What is clinical trial NCT01421524 about?
NCT01421524 is a clinical study titled "Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma". The main purpose of this first in human study with CC-122 is to assess the safety and action of a new class of experimental drug (Pleiotropic Pathway Modulator) in patients with advanced tumors unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-sta...
What is the current status of trial NCT01421524?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 271 participants. The study started on 2011-09-12. Estimated completion is 2023-11-21.
What conditions does trial NCT01421524 study?
This clinical trial studies the following conditions: Multiple Myeloma, Lymphoma, Glioblastoma, Primary Central Nervous System Lymphoma, Lymphoma, Large B-Cell, Diffuse.
What interventions are being tested in trial NCT01421524?
The interventions under investigation include: CC-122 (DRUG).
Who is sponsoring clinical trial NCT01421524?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01421524 being conducted?
This trial has 20 study locations across California, Michigan, Nevada, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.